$Biogen (BIIB.US)$ Canaccord Genuity analyst Sumant Kulkarni...
$Biogen(BIIB.US$ Canaccord Genuity analyst Sumant Kulkarni maintained a "buy" rating on Biogen with a $390 price target.
Earlier, South Korean media reported that Samsung group was in talks to buy Biogen, which it said would be valued at about $42 billion. Samsung Bio, a subsidiary of Samsung, later said the information was untrue.
Kulkarni said the expectation of "possible interest from strategic players" should provide at least some support for Biogen's stock, and downside should be limited.
Earlier, South Korean media reported that Samsung group was in talks to buy Biogen, which it said would be valued at about $42 billion. Samsung Bio, a subsidiary of Samsung, later said the information was untrue.
Kulkarni said the expectation of "possible interest from strategic players" should provide at least some support for Biogen's stock, and downside should be limited.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
